Graduate Spotlight: Biocytogen

Powered by cutting-edge gene editing technologies, Biocytogen was founded at MBI in 2008 to provide custom gene editing services to clients. After graduating from MBI, Biocytogen established its headquarters in Beijing, and opened sites in greater Boston and Shanghai in 2018. During this period, the company developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including generation of humanized animal and cell models, therapeutic antibody discovery (via its RenMice® technology platform, which includes RenMabTM, RenLite®, and RenNano® mice), and in vivo/in vitro preclinical validation studies.      

Biocytogen continues to grow, and supplies quality products and services to the life sciences cluster that runs from Cambridge to Worcester from its main U.S. site in Waltham, MA. In addition to its presence in the Commonwealth, Biocytogen has expanded globally, with satellite offices in Germany and California. In 2022, Biocytogen completed an IPO on the Hong Kong Stock Exchange.

In 2023, Biocytogen donated $375,000 to MBI’s Blue Beaker Campaign to help fund the development of its pilot Biomanufacturing Center.